NORTH AMERICA INJECTABLE DRUG DELIVERY MARKET 2019-2028

Lifesciences | Pharmaceuticals

NORTH AMERICA INJECTABLE DRUG DELIVERY MARKET 2019-2028

Market By Device Type, Route Of Administration, End-user, And Country | Forecast 2019-2028

Request Free Sample

Request Custom Report

Request Custom Report

Enquire before buying

Enquire Before Buying

Triton Market Research, in its report on the injectable drug delivery market in North America, has concluded that it would grow at a CAGR of 8.26% in the estimated years 2019-2028.


           Canada

           The United States

Countries in the North American region are have reached far ahead in terms of technology adoption, as compared to other countries in the world. They have an advanced healthcare infrastructure and are known to invest heavily in healthcare; therefore, this market accounts for the highest revenue in the global market for injectable drug delivery. As per the National Institute of Health (NIH), around 23.5 million Americans were found to be affected by the autoimmune disease in 2017. And this number is steadily on the rise. Most biologic drugs used for treating these conditions are administered using injectable drug delivery devices. Thus, the rise in the prevalence of autoimmune diseases is propelling the market growth in the United States.

Of late, biologic medications have been receiving approvals from regulatory authorities and are increasingly being commercialized. This has increased the demand for self-injection devices in the country. The National Health Council states that chronic diseases are the leading cause of disability and death in the US, accounting for 7 out of every 10 deaths, and killing over 1.7 million Americans each year. Furthermore, the geriatric population in the country is surging. The US’ Census Bureau predicts the country’s older population to reach 80 million by 2050. Older adults are more prone to diseases and infections, and they prefer self administration to visit a healthcare facility for drug administration. Therefore, the increase in cases of chronic diseases and the rise in the elderly population are enhancing the demand for injectable drug delivery devices.

Eli Lilly and Company is engaged in developing, manufacturing, and marketing pharmaceutical products and animal health products. In the field of injectable drug delivery, it offers solutions such as BASAGLAR, Humalog, and GLYXAMBI. The US-based company is headquartered in Indianapolis, Indiana. With strong R&D capabilities, the company is looking to expand its footprint globally.

Related Reports

ASIA PACIFIC AESTHETIC LASER MARKET 2019-2027
Lifesciences

ASIA PACIFIC AESTHETIC LASER MARKET 2019-2027

Market By Type, Application, E ..

VIEW REPORT
ASIA PACIFIC BIOCHIPS MARKET 2019-2027
Lifesciences

ASIA PACIFIC BIOCHIPS MARKET 2019-2027

Market By Type, Substrate Mate ..

VIEW REPORT
ASIA PACIFIC BIOPSY DEVICE MARKET 2019-2027
Lifesciences

ASIA PACIFIC BIOPSY DEVICE MARKET 2019-2027

Market By Device Type, Therape ..

VIEW REPORT
ASIA PACIFIC DNA VACCINES MARKET 2019-2027
Lifesciences

ASIA PACIFIC DNA VACCINES MARKET 2019-2027

Market By Type, Application, T ..

VIEW REPORT
ASIA-PACIFIC 3D CELL CULTURE MARKET 2019-2027
Lifesciences

ASIA-PACIFIC 3D CELL CULTURE MARKET 2019-2027

Market By Technology, Applicat ..

VIEW REPORT
ASIA-PACIFIC AIRWAY CLEARANCE SYSTEM MARKET 2019-2028
Lifesciences

ASIA-PACIFIC AIRWAY CLEARANCE SYSTEM MARKET 2019-2028

Market By Application, Type, E ..

VIEW REPORT

Table of Content

1.    NORTH AMERICA INJECTABLE DRUG DELIVERY MARKET - SUMMARY

2.    INDUSTRY OUTLOOK

2.1. MARKET DEFINITION

2.2. PORTER’S FIVE FORCES MODEL

2.2.1.   THREAT OF NEW ENTRANT

2.2.2.   THREAT OF SUBSTITUTE

2.2.3.   BARGAINING POWER OF BUYERS

2.2.4.   BARGAINING POWER OF SUPPLIERS

2.2.5.   INTENSITY OF COMPETITIVE RIVALRY

2.3. KEY INSIGHT

2.4. KEY BUYING CRITERIA

2.5. REGULATORY FRAMEWORK

2.6. MARKET ATTRACTIVENESS INDEX

2.7. MARKET DRIVERS

2.7.1.   INCREASING GERIATRIC POPULATION

2.7.2.   TECHNOLOGICAL ADVANCEMENT

2.7.3.   GROWING OCCURRENCE OF AUTOIMMUNE DISEASES

2.8. MARKET RESTRAINTS

2.8.1.   HIGH MANUFACTURING COST OF INJECTABLE DRUG DELIVERY SYSTEMS

2.9. MARKET OPPORTUNITIES

2.9.1.   DEVELOPMENT OF BETTER INJECTABLE SYSTEMS

2.9.2.   INCREASE IN HEALTHCARE EXPENDITURE

2.10. MARKET CHALLENGES

2.10.1. DEVELOPMENTS IN ALTERNATE DRUG DELIVERY SYSTEMS

2.10.2.  STRINGENT REGULATIONS

3.    INJECTABLE DRUG DELIVERY MARKET OUTLOOK - BY DEVICE TYPE

3.1. PEN INJECTOR

3.2. AUTO-INJECTOR

3.3. NEEDLE-FREE INJECTOR

3.4. PREFILLED SYRINGE

4.    INJECTABLE DRUG DELIVERY MARKET OUTLOOK - BY ROUTE OF ADMINISTRATION

4.1. SUBCUTANEOUS

4.2. INTRAMUSCULAR

4.3. INTRAVENOUS (IV)

4.4. OTHER ROUTE OF ADMINISTRATION

5.    INJECTABLE DRUG DELIVERY MARKET OUTLOOK - BY END-USER

5.1. CLINICS/ PHYSICIAN OFFICES

5.2. AMBULATORY CARE

5.3. HOSPITAL

5.4. HOME-BASED

5.5. OTHER END-USERS

6.    INJECTABLE DRUG DELIVERY MARKET – NORTH AMERICA

6.1. COUNTRY ANALYSIS

6.1.1.   THE UNITED STATES

6.1.2.   CANADA

7.    COMPANY PROFILES

7.1. BAXTER INTERNATIONAL INC

7.2. BECTON DICKINSON AND COMPANY (BD)

7.3. ELCAM MEDICAL

7.4. ELI LILLY AND COMPANY

7.5. GERRESHEIMER

7.6. INJEX

7.7. NOVARTIS AG

7.8. NOVO NORDISK A/S

7.9. PFIZER INC

7.10. SANOFI SA

7.11. SCHOTT AG

7.12. TERUMO CORPORATION

7.13. TEVA PHARMACEUTICALS

7.14. WEST PHARMACEUTICALS

7.15.  YPSOMED HOLDING AG

8.    RESEARCH METHODOLOGY & SCOPE

8.1. RESEARCH SCOPE & DELIVERABLES

8.1.1.   OBJECTIVES OF STUDY

8.1.2.   SCOPE OF STUDY

8.2. SOURCES OF DATA

8.2.1.   PRIMARY DATA SOURCES

8.2.2.   SECONDARY DATA SOURCES

8.3. RESEARCH METHODOLOGY

8.3.1.   EVALUATION OF PROPOSED MARKET

8.3.2.   IDENTIFICATION OF DATA SOURCES

8.3.3.   ASSESSMENT OF MARKET DETERMINANTS

8.3.4.   DATA COLLECTION

8.3.5.   DATA VALIDATION & ANALYSIS

List of table

TABLE  1       NORTH AMERICA INJECTABLE DRUG DELIVERY MARKET, BY REGION, 2019-2028 ($ MILLION)

TABLE  2       NORTH AMERICA INJECTABLE DRUG DELIVERY MARKET, BY DEVICE TYPE, 2019-2028 ($ MILLION)

TABLE  3       DIFFERENT TYPES OF INSULIN PEN INJECTORS

TABLE  4       MARKETED NEEDLE-FREE INJECTORS PRODUCTS

TABLE  5       LYOPHILIZED DRUGS WHICH ARE USED IN PREFILLED SYRINGE

TABLE  6       NORTH AMERICA INJECTABLE DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 ($ MILLION)

TABLE  7       NORTH AMERICA INJECTABLE DRUG DELIVERY MARKET, BY END-USER, 2019-2028 ($ MILLION)

TABLE  8       NORTH AMERICA INJECTABLE DRUG DELIVERY MARKET, BY COUNTRY, 2019-2028 ($ MILLION)   

List of Figures

FIGURE  1     NORTH AMERICA INJECTABLE DRUG DELIVERY MARKET 2019-2028 ($ MILLION)

FIGURE  2     KEY BUYING IMPACT ANALYSIS

FIGURE  3     NORTH AMERICA INJECTABLE DRUG DELIVERY MARKET, BY PEN INJECTOR, 2019-2028 ($ MILLION)

FIGURE  4     NORTH AMERICA INJECTABLE DRUG DELIVERY MARKET, BY AUTO-INJECTOR, 2019-2028 ($ MILLION)

FIGURE  5     NORTH AMERICA INJECTABLE DRUG DELIVERY MARKET, BY NEEDLE-FREE INJECTOR, 2019-2028 ($ MILLION)

FIGURE  6     NORTH AMERICA INJECTABLE DRUG DELIVERY MARKET, BY PREFILLED, 2019-2028 ($ MILLION)

FIGURE  7     NORTH AMERICA INJECTABLE DRUG DELIVERY MARKET, BY SUBCUTANEOUS, 2019-2028 ($ MILLION)

FIGURE  8     NORTH AMERICA INJECTABLE DRUG DELIVERY MARKET, BY INTRAMUSCULAR , 2019-2028 ($ MILLION)

FIGURE  9     NORTH AMERICA INJECTABLE DRUG DELIVERY MARKET, BY INTRAVENOUS , 2019-2028 ($ MILLION)

FIGURE  10  NORTH AMERICA INJECTABLE DRUG DELIVERY MARKET, BY OTHER ROUTE OF ADMINISTRATION, 2019-2028 ($ MILLION)

FIGURE  11  NORTH AMERICA INJECTABLE DRUG DELIVERY MARKET, BY CLINICS/PHYSICIAN OFFICES, 2019-2028 ($ MILLION)

FIGURE  12  NORTH AMERICA INJECTABLE DRUG DELIVERY MARKET, BY AMBULATORY CARE, 2019-2028 ($ MILLION)

FIGURE  13  NORTH AMERICA INJECTABLE DRUG DELIVERY MARKET, BY HOSPITAL, 2019-2028 ($ MILLION)

FIGURE  14  NORTH AMERICA INJECTABLE DRUG DELIVERY MARKET, BY HOME-BASED, 2019-2028 ($ MILLION)

FIGURE  15  NORTH AMERICA INJECTABLE DRUG DELIVERY MARKET, BY OTHER END-USER, 2019-2028 ($ MILLION)

FIGURE  16  THE UNITED STATES INJECTABLE DRUG DELIVERY MARKET 2019-2028 ($ MILLION)

FIGURE  17  CANADA INJECTABLE DRUG DELIVERY MARKET 2019-2028 ($ MILLION)

Purchase Options

  • Licence Type
  • Price
  • User/Sharing
  • Printing
  • Delivery Formats
  • Free customization (Pre-sale)
  • Analyst hour support (Post Sale)
  • Customized notification for newly published report
  • Free report on update (within 180 days)

Single User PDF

$1,500.00

  • User/Sharing
  • Restricted to one authorized user
  • Printing
  • Not printable
  • Delivery Formats
  • Pdf
  • Free customization (Pre-sale)
  • 10% Free customization
  • Analyst hour support (Post Sale)
  • 3 hours
  • Customized notification (newly published)
  • Free report on update (within 180 days)

Enterprise Online/PDF

$2,200.00

  • User/Sharing
  • Unlimited
  • Printing
  • Unlimited
  • Delivery Formats
  • Pdf and market estimation excel
  • Free customization (Pre-sale)
  • 20% Free customization
  • Analyst hour support (Post Sale)
  • 8 hour
  • Customized notification (newly published)
  • Free report on update (within 180 days)

Request free Sample

SUBMIT REQUEST
Request Custom Report

Request Custom Report

Enquire before buying

Enquire Before Buying

;